Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
23 May 2024 - 9:30PM
Business Wire
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA
and genetic testing, today announced that the company, along with
its collaborators, will present new data at the 2024 American
Society of Clinical Oncology (ASCO) Annual Meeting taking place May
31 – June 4, 2024.
The presentations feature data across a variety of indications,
including breast cancer, colorectal cancer (CRC), lung cancer,
melanoma, esophageal cancer, and urothelial cancer, with one oral
presentation and 12 poster presentations on Signatera™, Natera’s
personalized and tumor-informed molecular residual disease test, as
well as one poster with data on Empower™, Natera’s test for
hereditary cancer.
Minetta Liu, MD, chief medical officer of oncology at Natera,
said, “We look forward to sharing new data across cancer types,
reflecting Natera's deep clinical pipeline in MRD with results from
randomized trials as well as real-world studies. This includes
promising new findings from the CIRCULATE-Japan GALAXY study
demonstrating the prognostic and predictive utility of Signatera
and actionable biomarkers in colorectal cancer.”
GALAXY is part of the CIRCULATE-Japan trial platform, which also
includes ALTAIR, a first-of-its-kind, “treat on molecular
recurrence” study evaluating the utility of Signatera in CRC.
Natera expects to announce topline results for this phase III
randomized trial in August 2024.
Below is the full list of presentations
featuring Signatera and Empower at ASCO:
- Poster Presentation | Abstract # 3609 | Presenter: Yoshiaki
Nakamura, MD, PhD | CRC Prognostic and predictive value of
ctDNA-based MRD and actionable biomarkers in patients with
resectable CRC: CIRCULATE-Japan GALAXY
- Oral Presentation | Abstract # LBA507 | Presenter: Sherene
Loi, MD, PhD | Breast Cancer Prognostic utility of ctDNA
dynamics in the monarchE trial of adjuvant abemaciclib plus
endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk
early breast cancer (EBC)
- Poster Presentation | Abstract # 3586 | Presenter: Eric
Lander, MD | CRC Genomic alterations in early-onset versus
average-onset stage IV CRC
- Poster Presentation | Abstract # 5034 | Presenter: Rebecca
Hassoun, MD | Testicular Cancer Longitudinal Evaluation of
ctDNA as a Prognostic Biomarker to Detect Minimal Residual Disease
(MRD) in Testicular Cancer
- Poster Presentation | Abstract # 4587 | Presenter: Adanma
Ayanambakkam, MD | Urothelial Cancer Longitudinal analysis of
ctDNA in localised and metastatic urothelial cancer
- Poster Presentation | Abstract # 4028 |
Presenter: Aziz Zaanan, MD | Esophageal Cancer
Longitudinal ctDNA analysis during treatment (Tx) of locally
advanced resectable (LAR) gastric or gastroesophageal junction
(G/GEJ) adenocarcinoma (ADENOCA): the PLAGAST prospective biomarker
study
- Poster Presentation | Abstract # 9564 | Presenter: Michael
LaPelusa, MD | Melanoma Association between ctDNA and
Recurrence-Free Survival (RFS) in Patients (pts) with Resected
Stage III Melanoma - an Exploratory Analysis of SWOG S1404
- Poster Presentation | Abstract # 6056 | Presenter: Glenn
Hanna, MD | Head and Neck Squamous Cell Carcinoma Personalized
ctDNA for monitoring disease status in HPV-negative head and neck
squamous cell carcinoma
- Poster Presentation | Abstract # TPS8659 | Presenter:
Yasushi Goto, MD, PhD | Lung Cancer Randomized phase III study
comparing suspension or continuation of PD- 1 Pathway Blockade for
patients with advanced non-small-cell lung cancer (SAVE study:
JCOG1701)
- Poster Presentation | Abstract # 569 | Presenter: Mridula
George, MD | Breast Cancer Predicting response to neoadjuvant
therapy (NAT) in patients (pts) with early-stage breast cancer (BC)
using ctDNA testing
- Poster Presentation | Abstract # 549 | Presenter: Marla
Lipsyc-Sharf, MD | Breast Cancer Impact of ctDNA surveillance
on clinical care for patients with stage I-III breast cancer:
Findings from a multi-institutional study.
- Poster Presentation | Abstract # 518 | Presenter: Yoichi
Naito, MD | Breast Cancer ctDNA monitoring for breast cancer at
high risk of recurrence: Interim analysis of JCOG1204A1
- Poster Presentation | Abstract # 10596 | Presenter: Sarah
Lee, MD | Pan-Cancer (Empower) A targeted panel of actionable
high risk hereditary cancer predisposition genes can identify
patients with pathogenic/likely pathogenic variants (PVs)
irrespective of meeting established NCCN testing criteria
About Signatera
Signatera is a personalized, tumor-informed, molecular residual
disease test for patients previously diagnosed with cancer.
Custom-built for each individual, Signatera uses circulating tumor
DNA to detect and quantify cancer left in the body, identify
recurrence earlier than standard of care tools, and help optimize
treatment decisions. The test is available for clinical and
research use and is covered by Medicare for patients with
colorectal cancer, breast cancer, ovarian cancer and muscle
invasive bladder cancer, as well as for immunotherapy monitoring of
any solid tumor. Signatera has been clinically validated across
multiple cancer types and indications, with published evidence in
more than 60 peer-reviewed papers.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing,
dedicated to oncology, women’s health, and organ health. We aim to
make personalized genetic testing and diagnostics part of the
standard-of-care to protect health and inform earlier, more
targeted interventions that help lead to longer, healthier lives.
Natera’s tests are supported by more than 200 peer-reviewed
publications that demonstrate excellent performance. Natera
operates ISO 13485-certified and CAP-accredited laboratories
certified under the Clinical Laboratory Improvement Amendments
(CLIA) in Austin, Texas, and San Carlos, California. For more
information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements and
are not a representation that Natera’s plans, estimates, or
expectations will be achieved. These forward-looking statements
represent Natera’s expectations as of the date of this press
release, and Natera disclaims any obligation to update the
forward-looking statements. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially, including with respect to
whether the results of clinical or other studies will support the
use of our product offerings, the impact of results of such
studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and
product offerings to patients, providers and payers. Additional
risks and uncertainties are discussed in greater detail in "Risk
Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in
other filings Natera makes with the SEC from time to time. These
documents are available at www.natera.com/investors and
www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523550998/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc.,
510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of
Corporate Communications, Natera, Inc., pr@natera.com
Natera (NASDAQ:NTRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Natera (NASDAQ:NTRA)
Historical Stock Chart
From Sep 2023 to Sep 2024